NZ595630A - Methods for preventing and/or treating degenerative disorders of the central nervous system - Google Patents

Methods for preventing and/or treating degenerative disorders of the central nervous system

Info

Publication number
NZ595630A
NZ595630A NZ59563010A NZ59563010A NZ595630A NZ 595630 A NZ595630 A NZ 595630A NZ 59563010 A NZ59563010 A NZ 59563010A NZ 59563010 A NZ59563010 A NZ 59563010A NZ 595630 A NZ595630 A NZ 595630A
Authority
NZ
New Zealand
Prior art keywords
nervous system
central nervous
preventing
methods
degenerative disorders
Prior art date
Application number
NZ59563010A
Inventor
Robert Boyd
Gary Lee
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16810109P priority Critical
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Priority to PCT/US2010/030470 priority patent/WO2010118282A1/en
Publication of NZ595630A publication Critical patent/NZ595630A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine

Abstract

Disclosed herein is the use of an effective amount of a therapeutic agent which is 5-(fluoromethyl)piperdine-3,4-diol, 5-(chloromethyl)piperdine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof for the manufacture of a medicament for the treatment of a degenerative disorder of the central nervous system in a patient at risk for developing or diagnosed with the same.
NZ59563010A 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system NZ595630A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16810109P true 2009-04-09 2009-04-09
PCT/US2010/030470 WO2010118282A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Publications (1)

Publication Number Publication Date
NZ595630A true NZ595630A (en) 2013-04-26

Family

ID=42934882

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ59563010A NZ595630A (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating degenerative disorders of the central nervous system

Country Status (12)

Country Link
US (1) US8304429B2 (en)
EP (1) EP2416655B1 (en)
JP (1) JP5634498B2 (en)
CN (1) CN102448306B (en)
AU (1) AU2010233187B2 (en)
BR (1) BRPI1015472A2 (en)
CA (1) CA2758187C (en)
ES (1) ES2505243T3 (en)
HK (1) HK1168005A1 (en)
IL (1) IL215584A (en)
NZ (1) NZ595630A (en)
WO (1) WO2010118282A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118283A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
MX337933B (en) * 2009-10-19 2016-03-29 Amicus Therapeutics Inc Novel compositions for preventing and/or treating lysosomal storage disorders.
RU2015147509A (en) * 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Novel compositions for the prevention and / or treatment of degenerative disorders of the central nervous system
CA2817960A1 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2013070981A2 (en) * 2011-11-08 2013-05-16 University Of Central Florida Research Foundation, Inc. Treating er stress related disorders by stabilizing intracellular calcium homeostasis
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
WO2015095963A1 (en) 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT243196T (en) * 1994-03-09 2003-07-15 Novo Nordisk As Piperidines and pyrrolidines
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6670625B1 (en) * 2002-06-18 2003-12-30 Ge Medical Systems Global Technology Company, Llc Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner
AU2003273762A1 (en) * 2002-10-28 2004-05-13 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
DK2040548T3 (en) * 2006-06-23 2012-08-13 Amicus Therapeutics Inc A method for the treatment of neurological disorders by increasing the activity of beta-glucocerebrosidase
US20080009156A1 (en) 2006-07-10 2008-01-10 Malin Glen K System and method for bonding coaxial cable
WO2010118283A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders

Also Published As

Publication number Publication date
EP2416655B1 (en) 2014-06-25
JP2012523430A (en) 2012-10-04
CN102448306A (en) 2012-05-09
IL215584A (en) 2016-11-30
CN102448306B (en) 2014-07-02
EP2416655A4 (en) 2012-09-05
BRPI1015472A2 (en) 2015-11-24
ES2505243T3 (en) 2014-10-09
US8304429B2 (en) 2012-11-06
CA2758187A1 (en) 2010-10-14
CA2758187C (en) 2017-03-07
AU2010233187B2 (en) 2015-10-08
HK1168005A1 (en) 2015-07-10
EP2416655A1 (en) 2012-02-15
IL215584D0 (en) 2011-12-29
JP5634498B2 (en) 2014-12-03
AU2010233187A1 (en) 2011-11-03
WO2010118282A1 (en) 2010-10-14
US20100261753A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
NZ600257A (en) Device and method for delivery of two or more drug agents
GB2467670A (en) Chemical entities and therapeutic uses thereof
NZ589309A (en) New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
TW201008563A (en) Composite lacrimal insert and related methods
TW200526238A (en) Combination therapy for treatment of ocular neovascular disorders
MX2014002542A (en) Heterocyclic compounds and uses thereof.
WO2012065177A3 (en) Stabilized ablation systems and methods
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
EA017264B1 (en) Use of arylcycloalkylamide composition for preparing a medicament for the treatment of inner ear disorder
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
TW200533362A (en) Use of meloxicam for the treatment of respiratory diseases in pig
WO2010042471A3 (en) Medical devices for delivery of therapeutic agents to body lumens
MX352789B (en) Diagnosis and treatments relating to th2 inhibition.
MXPA06011216A (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease.
MX2011014004A (en) Compositions and methods for modulation of smn2 splicing in a subject.
AU2010282948B2 (en) Treatment of BDNF-related disorders using laquinimod
MX2011006167A (en) Combinations and modes of administration of therapeutic agents and combination therapy.
TW200904440A (en) Method for modulating GPR119 G protein-coupled receptor and selected compounds
EA023559B1 (en) Human insulin analogues of prolonged therapeutical activity, stable in acidic medium
EA020489B1 (en) Modulators of pharmacokinetic properties of therapeutics
EP2142244A4 (en) Medical device for delivering drug and/or performing physical therapy
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
UA116017C2 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE AGENT HAS BEEN CORRECTED TO 1441794, IPONZ, 2. , 205 VICTORIA STREET, TE ARO, WELLINGTON 6011, NZ; 1028818, WRAYS, WRAYS #1701, 24B MOOREFIELD ROAD, JOHNSONVILLE, WELLINGTON 6037, NZ

Effective date: 20130404

Free format text: THE AGENT HAS BEEN CORRECTED TO 1028818, WRAYS, WRAYS #1701, 24B MOOREFIELD ROAD, JOHNSONVILLE, WELLINGTON 6037, NZ

Effective date: 20130404

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 APR 2017 BY CPA GLOBAL

Effective date: 20140306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2018 BY CPA GLOBAL

Effective date: 20170303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2019 BY CPA GLOBAL

Effective date: 20180301